决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Enhanced anti-liver tumor efficacy of chimeric antigen receptor-T cells via SATB1 modulation.
我们的研究揭示了SATB1作为一个多功能调节因子,同时靶向耗竭和记忆分化,为增强CAR-T对抗实体瘤的疗效提供了一种新策略。
尽管嵌合抗原受体(CAR)T细胞疗法在治疗血液系统恶性肿瘤方面取得了显著成功,但其在实体瘤中的临床应用受到免疫抑制性肿瘤微环境(TME)中持续性T细胞耗竭的严重阻碍。在此,我们鉴定出SATB1——一个调控染色质架构的基因组组织者——是CAR-T细胞耗竭的关键抑制因子。在靶向Glypican-3(GPC3)的CAR-T细胞中,SATB1在肿瘤浸润性耗竭细胞群中显著下调。SATB1过表达不仅降低了多种抑制性受体(PD-1、CTLA-4、TIM3和LAG-3)的表达,还促进了中央记忆表型,增强了体外对肝细胞癌(HCC)细胞的细胞因子产生和细胞毒性。在体内,SATB1工程化CAR-T细胞表现出更优的肿瘤控制能力并促进生存,同时肿瘤浸润性T细胞中的耗竭标志物减少。这些功能改善与SATB1在调节T细胞耗竭中的已知作用一致,使其成为CAR-T细胞适应性的多功能增强因子。总之,我们的研究揭示了SATB1作为一个多功能调节因子,同时靶向耗竭和记忆分化,为增强CAR-T对实体瘤的疗效提供了一种新策略。
Although Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable success in treating hematopoietic malignancies, its clinical application in solid tumors is profoundly hindered by persistent T-cell exhaustion within the immunosuppressive tumor microenvironment (TME). Here, we identified SATB1-a genome organizer regulating chromatin architecture-as a key suppressor of CAR-T cell exhaustion. In Glypican-3 (GPC3)-targeted CAR-T cells, SATB1 was significantly downregulated in tumor-infiltrating exhausted populations. SATB1 overexpression not only reduced expression of multiple inhibitory receptors (PD-1, CTLA-4, TIM3, and LAG-3) but also promoted a central memory phenotype, enhancing cytokine production and cytotoxicity against hepatocellular carcinoma (HCC) cells in vitro. In vivo, SATB1-engineered CAR-T cells exhibited superior tumor control and promoted survival, accompanied by reduced exhaustion markers in tumor-infiltrating T cells. These functional improvements are consistent with the reported role of SATB1 in modulating T cell exhaustion, positioning it as a multifunctional enhancer of CAR-T cell fitness. Collectively, our study unveils SATB1 as a multifunctional modulator that simultaneously targets exhaustion and memory differentiation, offering a novel strategy to enhance CAR-T efficacy against solid tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。